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1Cosmeceuticals or CosmePSEUDOcals: Examining the FDA’s Under-sight of Celebrity
Dermatologists in the Cosmeceuticals Industry
Abstract
This paper will examine the Food and Drug Administration’s regulation of the cosmeceuticals industry by
exploring the legal (and ethical) implications of the industry’s employment of physicians and dermatologists
who sell products which the doctors themselves have a ﬁnancial stake in. By focusing on famed dermatologist,
cosmeceutical entrepreneur, and bestselling author Dr. Nicholas Perricone, this paper will elucidate the legal
repercussions of using doctors to market and legitimize the drug-like claims of products that are in essence,
just gloriﬁed cosmetics.
Introduction; Beholders v. Shareholders In the cosmeceutical in-
dustry
While beauty may be in the eye of the beholder, the money is objectively ﬂying into the hands of the
corporate cosmeceutical shareholders, corporations, and their paid entourage of star dermatologists. The
cosmetics industry used to focus on hawking hot pink lipsticks and lash-extending mascara. But now the
industry has grown up. Rather than just hiding imperfections, the new age of cosmetics products, known
as cosmeceuticals, claim to ﬁght imperfections. Men and women are rushing to cosmeceuticals counters to
anti-wrinkle creams, Alpha Hydroxy Acids, Botox, and the like.1 Cosmeceuticals are generally regarded
1See Special Report: Skin Care’s Changing Face, Business Week Online, http://images.businessweek.com/db/04/11/cosmeceutical/cosmeceutical01.htm?thisSpeed=9000
(last visited May 5, 2005).
2as cosmetics with medicinal or drug-like beneﬁts.2 The industry promises that its products are the new
fountain of youth and consumers are handing over billions of dollars in accord. But with the wide array of
(high priced) cosmeceutical products to choose from, consumers must rely on outside experts to help guide
their decisions.
Unfortunately, the Food and Drug Administration (FDA), the agency that administrates the requirements of
the Food, Drug, and Cosmetics Act of 1906, does not actively review the inﬂated claims of cosmeceutical man-
ufacturers. Recognizing this loophole in FDA regulation, cosmetics companies have employed dermatologists
to legitimize their overstated claims before consumers. Consumers, in turn, rely on the recommendations of
these medical professional in paying upwards of $25 to $400 per bottle to cosmeceutical companies.
This paper explores the legality marketing practices of cosmeceutical industry i.e. making drug-like claims
about products that are merely gloriﬁed cosmetics, and using doctors to market and legitimize the drug-
like claims. The ﬁrst part of this paper discusses the “under-sight” of the cosmeceutical industry and the
industry’s questionable use of dermatologists to promote cosmetics for proﬁt. The second section explores
the growing empire of a well-known dermatologist, cosmeceutical entrepreneur, and bestselling author Dr.
Perricone, to highlight the consequences of the business relationship between the cosmeceuticals and derma-
tologists. Ultimately, the paper argues that because the marketing practices may confuse consumers about
the nature of the cosmeceuticals they purchase, the FDA should regulate the industry.
2See Cosmeceuticals, Oﬃce of Cosmetics and Colors Fact Sheet U.S. Food and Drug Administration –
Center for Food Safety and Applied Nutrition February 3, 1995; revised February 24, 2000) available at
http://www.cfsan.fda.gov/∼dms/cos-217.html (last visited April 30, 2005).
3PART I.
A. Do You “Drugs” take “Cosmetics” to be your Lawfully Wedded
Partner?: background on law regarding cosmeceuticals
Although the so-called cosmeceutical industry is booming, the FDA does not actually recognize the term
cosmeceutical3 nor is there an oﬃcial deﬁnition for the word. Instead, the cosmeceutical industry exists
in a state of regulatory limbo: at times they are regulated as drugs, but most often they are regulated
as cosmetics.4 And in the absence of an oﬃcial deﬁnition, the industry is essentially free to massage and
manipulate the deﬁnition as it pleases. Thus synonyms like “quasi-drugs,” “therapeutic cosmetics,” “cosmetic
drugs,” “active skin treatment,”5 and “cosmetics with pharmaceutical beneﬁts”6 abound in the marketing
of cosmeceuticals.
The FDA has created new regulatory space for some of the latest “combination products” such as drug-devices
and biologic-drugs -7 but it has not done so for cosmeceuticals. The agency instead regulates cosmeceuticals
3www.fda.gov.
4Many cosmeceuticals are created by cosmetics companies. See Carol Rados, Science Meets Beauty:
Using Medicine to Improve Appearances, FDA Consumer Magazine (March-April 2004) available at
http://www.fda.gov/fdac/features/2004/204 beauty.html (last visited May 5, 2005).
There are, however, cosmeceuticals that are created by pharmaceutical companies. The Dermagenetics line of “genetically
customized” skin care products is an example. The fact that the parent company, GeneLink, Inc., is a genetic-biosciences
company with a focus on biomedical projects and that Pharmaceutical companies and Hospitals are amongst its primary
customers would suggest to most that this is more of a drug like product. However, as this speciﬁc line of “genetically
customized” skin care products are solely being marketed as just that, skin care products, this product will likely be classi-
ﬁed as cosmetic. For more information see Cosmeceuticals: Dermagenetics Launched at ISPA Convention, Biotech Business
Week (December 20, 2004) (hereinafter Dermagenetics Article), see also, Corporate Proﬁle, Gene Link, Inc., available at
http://www.genelink.com/newsite/corporate.asp (last visited April 30, 2005).
5Santiago A. Centurion, MD, Cosmeceuticals (last updated February 4, 2004) available at
http://www.emedicine.com/derm/topic509.htm (last visited April 30, 2005).
6Nora Caley, More Than Skin Deep; Company’s ‘Cosmeceuticals’ Aimed at High-End Market, Rocky Mountain News (April
19, 1998) (quoting Francine Porter, owner of Osmotics).
7Recognizing that technological advances are continuously merging the lines between therapeutic products FDA’s Oﬃce of
Combination Products was created to regulate these “combination products.” But its jurisdiction only covers combinations of
4through its traditional regulatory categories: either cosmetics, drugs, or a combination of both. If the status
of a product is challenged, the agency will either determine if a product held out by a company as a cosmetic
is “misbranded” or if it is in fact a drug.8
Drugs and cosmetics undergo very diﬀerent regulatory treatments. Drugs are “(A) articles intended for use
in the diagnosis, cure, mitigation, treatment, or prevention of disease...and (B) articles (other than food)
intended to aﬀect the structure or any function of the body of man or other animals.”9 Before they are
released to the market, they must undergo a burdensome, cost intensive regulatory process.10 In contrast,
cosmetics, including “creams, lotions, powders and sprays; perfume; lipstick; [and] ﬁngernail polish,”11 are
statutorily deﬁned as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or
otherwise applied to the human body ...for cleansing, beautifying, promoting attractiveness, or altering the
appearance.”12 Unlike drugs, the FDA does not review or approve cosmetics before they reach consumers.
In fact, cosmetics do not even have to be proven safe before they reach paying consumers.13 It is therefore
less costly for cosmetics companies to market their cosmeceuticals products as cosmetics, rather than drugs,
because they can avoid FDA oversight.
A cosmeceutical’s “intended use” – gleaned from the labeling, advertising, promotional materials – determines
the regulatory fate of a cosmeceutical as a cosmetic or drug. 14 The actual physical eﬀect of the product
drug-device, biologic-device, drug-biologic, and drug-device-biologic. See 21 C.F.R. § 3.2(e). See also Overview of the Oﬃce of
Combination Products available at http://www.fda.gov/oc/combination/overview.html (last visited April 30, 2005).
8See generally, See Byran A. Liang, It’s Only Skin Deep: FDA Regulation of Skin Care Cosmetics Claims, 8 Cornell J.L. &
Pub. Pol’y 249, 252 (1999).
921 U.S.C. § 321 (g)(1)
10See Robert Higgs, Hazardous to Our Health, 15 (The Independent Institute 1995) (a drug company must receive pre-market
approval for claims made about the drug, it must demonstrate that the product is eﬃcacious for all claimed indications, and it
will be subject to clinical trial regulations).
11Carol Rados, supra note 4.
1221 U.S.C. § 321 (i)
13Carol Rados, supra note 4.
14See Liang, supra note 8, at 252 (citing United States v. An Article ...Consisting of 216 Individually Cartoned Bottles,
5has no bearing on its intended use.15 Therefore, cosmeceuticals might indeed have skin altering properties,
but so long as the manufacturers are careful in their advertising claims, they will not have to worry about
FDA oversight.16
B. A Cosmetic By Any Other Name Would Smell... Fishy: a look
at the misleading nature of the term “cosmeceutical”
It is the job of the FDA to “protect the unwary customer”17 against a company’s false and misleading
claims. A company must consider how the “ignorant, the unthinking, and the credulous”18 consumers will
understand the products’ claims. In fact, even if a product’s name impliedly (but falsely) claims that it is
eﬀective at achieving a speciﬁed outcome, may render it misbranded.19 In that light, when the industry
appends “ceutical” (which deceptively implies that the FDA regulates the products in the same manner as
pharmaceutical drugs) to refer to products that the FDA in actuality regards as mere cosmetics is a legally
questionable practice.20
In order to understand consumer perceptions of “cosmeceuticals”, I informally surveyed eleven college ed-
ucated consumers about what they thought the term “cosmeceutical” meant. Their responses reveal that
More or Less, of an Article Labeled in Part: Sudden Change, 288 F.Supp. 29 (E.D.N.Y. 1968) (hereinafter referred to as
“Sudden Change”).
15See id.
16See e.g. http://www.cfsan.fda.gov/∼dms/cos-217.html (last visited April 30, 2005).
Donald P. Hensel, FDA Regulation and the New Anti-Aging Products, Food and Drug Law: An Electronic Book of
Student Papers, available at http://leda.law.harvard.edu/leda/data/93/dhensel.pdf (1995) (last visited March 23, 2005)
(discussing how the caustic nature of Alpha Hydroxy Acids is overlooked by the FDA because the manufacturers to not make
drug claims on the labeling).
17See Liang, supra note 8, at 252 – 253. (citing Sudden Change).
18See id.
19Peter Barton Hutt and Richard A. Merrill, Food and Drug Law: Case and Materials – Second Edition, (Foundation Press
1991), at 395 – 96 (citing United States v. 43 1
2 Gross...”Xcello’s Prophylactics,” 65 F.Supp 534 (D.Minn. 1946)).
20“Cosmeceutical,” which Dr. Perricone has registered with the Federal Government as his trademark, seems to be a deceptive
name under this theory.
6many consumers are unaware that the products are often times oﬃcially classiﬁed as simple “cosmetics.”
The participants mistakenly deﬁned cosmeceuticals a “medicated cosmetics,” “cosmetic prescription drugs,”
and “cosmetics with drugs.”21 If the terminology misled these college educated consumers, it is highly likely
that the average consumer, the “unthinking” consumer, and the “credulous” consumers are being similarly
confused.22 In fact, in the past years cosmeceutical sales vastly outstripped sales of regular cosmetics prod-
ucts,23 indicating that indeed consumers believe that they are purchasing signiﬁcantly diﬀerent than regular
cosmetics. Because they often promote their products as “cosmetics,” many cosmeceutical companies avoid
the strict regulatory requirements of “drugs,” while at the same time proﬁting from consumer perception
that the products are indeed drugs or that they have some type of “pharmaceutical beneﬁt.” Unfortunately
for unsuspecting consumers, the regulators seem to overlook the fact that the term cosmeceutical in and of
itself is a misleading term that should be cause for regulatory concern. In the absence of federal guidelines,
consumers are forced to rely on outside sources to guide their product purchases...
C. Is there a Dermatologist in the House?: a look at the misleading
nature of dermatologist promotions
Dermatologist recommendations are the Consumer’s Digest of the beauty industry. The same reasons that
we hold doctor recommendations in such high esteem are the very reasons that regulators should be wary
21Though some respondents did not extract the medical reference from the term, they did nonetheless ascribe some elevated
status to the word as they thought it might mean “able to teach cosmetics,” or the “study of cosmetics.” The remaining
responses were: “getting people to focus in on the medical side of cosmetics” and simply “cosmetics in the pharmacy.” Not one
person said simply “cosmetics.”
22Jacqueline A. Greﬀ, Regulation of Cosmetics that are also Drugs, 51 Food & Drug L.J. 243 (1996).
23See Sally Beatty, New Wrinkle – Hot at the Mall: Skin-Care Products from Physicians; Cosmeceutical Creams Tap Antiaging
Market; Questions About Claims; Dr. Perricone TV Specials, The Wall Street Journal, A.1 (Nov. 14, 2003) (stating that
“[s]ales of dermatologist and so-called clinical brands have exploded in the last year, becoming the fastest-growing segment
of the department store skin-care business. While total skin-care sales in department stores grew just 2.6% in 2002, sales of
dermatologist and clinical brands jumped 62% in the same period...”).
7of an industry that uses doctors to promote cosmetics for proﬁt. In fact, in other areas, doctors can be
held legally liable for referring patients to facilities in which they have a ﬁnancial stake.24 Cosmeceutical
customers are denied the same protections. Nevertheless, it is diﬃcult for consumers to assess the claims of
products and therefore they must rely on experts to guide their decisions.25 Because the FDA insuﬃciently
regulates these gloriﬁed cosmetics, from the consumers’ perspective, these expert recommendations serve as
a proxy for federal regulatory ﬁlters.
Recently, recognizing the large proﬁts to be extracted from the rapidly growing market, a number of large
cosmeceutical companies have rushed to incorporate the medically-trained into their entourage of salesper-
sons.26 A growing sect of dermatologists is bringing the industry, their own books, their products, and
their own image to celebrity status.27 Doctors such as Dr. Murad28 and Dr. Perricone are paraded before
consumers to emphasize the “ceutical” nature of products that are in actuality considered by the FDA as
nothing more than cosmetics. Thus, in addition to the misleading moniker, the FDA should be more con-
cerned with cosmeceuticals because they are being promoted by doctors whose presence could further act to
confuse consumers.
In order to protect consumers, the FDA imposes strict regulations on the relationship between pharmaceutical
companies, doctors, and the information exchanged between the two.29 There is no such proscription on the
24See generally, Sam A. Mackie, J.D., Liability of a Physician for Improper Referral of Patients to a Medical Care-Facility in
Which the Physician Has a Financial Interest, 61 Am. Jur. Proof of Facts 3d 245 (2004).
25Rados, Science supra note 4.
26Beatty, supra note 23 (noting that L’Oreal jumped on growing trend of hiring dermatologists and “hired Dr. Tina S. Alster,
who frequently give skin-care advice on daytime talk shows, as a dermatological consultant to help with product development
and department-store appearances [emphasis added]).
27Doctors such as Dr. Howard Murad, Dr. Fredric Brandt, and Dr. Nicholas Perricone. See Beatty, supra note 23. Dr.
Perricone will be discussed in more detail, infra page 9.
28For more information on Dr. Murad see http://www.murad.com/.
29See Hutt, supra note 19, at 458 (discussing FDA’s restrictions against pharmaceutical companies that in essence bribe
doctors with gifts and other promotionals in order to get the doctors to recommend their products to patients).
8relationship between cosmetics companies and doctors. These companies have signiﬁcantly more leeway in
recruiting doctors to promote their products. Of course medical professionals are prohibited from engaging
in false, fraudulent, deceptive, or misleading advertising, and advertising that would lower or demoralize
professional standards,30 but beyond that there are no speciﬁc ethical standards to which they are bound
that directly address the promotion of products and services.31 Thus, these doctors have tremendous latitude
with respect to their marketing practices. A large part of the problem is that FDA does not have jurisdiction
over the medical profession,;32 instead it is a task left to the whims of state legislatures33 – and even state
standards may be too vague to eﬀectively regulate doctors’ advertising practices.34 When consumers are
running to the cosmeceuticals counters in droves based solely on the assurances of these trained professionals,
the FDA should be concerned. To be sure, many medical professions may hesitate to use their status to
promote products for a proﬁt.
One should not underestimate the trust that beauty consumers, and the general public more generally place
in medical professionals. Indeed, doctors are legally regarded as “learned intermediaries” 35 who are liable
for ramiﬁcations of their advice and opinions given regarding risks and beneﬁts of products. In some sense,
we trust their professional expertise and good judgment to be the ﬁnal word on the products that they
recommend.36 Unfortunately for unsuspecting consumers, (and quite fortune-ately for the cosmeceutical
30Laura Hunter Dietz, J.D., et al, Advertising and Soliciting, 61 Am. Jur. 2d Physicians, Surgeons, and Other Healers §13
(updated 2004).
31See MORE http://www.ama-assn.org/ama/pub/category/2512.html. In contrast, the legal profession has sketched out
ethics standards that directly speak to the propriety of attorney advertising.
32See Peggy Chen, Education or Promotion? Industry-Sponsored Continuing Education (CME) as a Center For the
Core/Commercial Speech Debate, 58 Food & Drug L.J. 473, 473 (2003) (citing 21 U.S.C. §396 (2000) which states that
the Food, Drug, and Cosmetic Act (FDCA) “[shall not] be construed to limit or interfere with the authority of a healthcare
practitioner to prescribe or administer any legally marketed device to a patient for any condition of disease within a legitimate
healthcare practitioner - patient relationship.”) Instead, the medical profession is regulated by the states,
33See generally Dietz, supra note 30.
34See e.g. Amsel v. Brooks, 141 Conn. 288 (1954) (holding that state’s deﬁnition of “advertise” in the context of denture
sales through a licensed dentist was unconstitutional as it had no reasonable relation to public welfare).
35Kimberly Castelaz, J.D. et al, Learned-Intermediary Doctrine; Products Provided by Physicians, 63A Am. Jur. 2d Products
Liability §1200.
36Id.
9companies and doctors), learned-intermediary doctrine is likely inapplicable to physicians who promote
cosmeceuticals because these products are not prescription products.37 This is so despite the evidence that
consumers regard the products as something akin to “cosmetic prescription drugs,” supra page 6.
PART II
A. Enter Dr. Nicolas Perricone – The Celebrity Dermatologist
He can make you beautiful in twenty-eight days! The cosmeceutical industry is being rocketed to a new level
of fame by the promotion of Yale Medical School professor and New York Times best seller, Dr. Nicholas
Perricone.38 Coined the “celebrity dermatologist,”39 Dr. Perricone has made his indelible mark on the cos-
meceuticals ﬁeld. One need only conduct a cursory study of Dr. Perricone’s career and empire to understand
the distorting eﬀect that a dermatologists recommendation can have on the sale of cosmetics products. Ad-
vising consumers about the links between beauty, neurology, and health, he has a series of New York Times
Bestselling books.40 And his celebrity status is not limited to the reading public; Dr. Perricone lectures about
his theory television stations around the country.41 Indeed, in the ﬁve years since his media debut, sales of
his products reached the millions. Because he is considered the “father of cosmeceuticals”42 this paper will
37See id. (noting that “the learned-intermediary doctrine does not apply to nonprescription products give to a patient by a
physician, since it would be illogical to treat a plaintiﬀ diﬀerently based on the mere fortuity of attaining the product from his
or her physician”).
38See http://www.drperricone.com/drnvperricone.htm (last visited April 30, 2005).
39Joel Lang, The Perricone Formula: To Become a Cosmetics King, You Can’t Let Anybody Get Under Your Skin, Hartford
Courant (March 6, 2005).
40See Liang, supra note 8.
41See id.
42http://www.nvperriconemd.com/ (hereinafter referred to as “Perricone Online”) (“The Science” link, “Drug and Cosmetic
Industry” link) (last visited May 5, 2005). Interestingly enough, cosmeceuticals were in existence long before Perricone’s rise to
fame. Products ﬁrst arrived on the scene more than 22 years ago, when vitamin A was added to creams to help ﬁght wrinkles.
See Daniela Lamas, Cosmeceutical Controversy; Dermatologists walk a ﬁne line with skin-care product endorsements, The
Houston Chronical, p. 14 (October 8, 2003).
10focus on Dr. Perricone as a case study of the problems incumbent when doctors and proﬁt motives are mixed.
1.
Dr. Perricone - The Doctor
Most consumers would be impressed with the credentials of this “learned intermediary” and likely will make
purchases based on his recommendations – a reality that the FDA should be concerned about. The doctor
started his medical career in the halls of Michigan State University College of Human Medicine (where he
graduated in three years) and Yale University School of Medicine.43 Impressive, extensive, and available to
consumers worldwide, his online biography acts to legitimize and bolster any claims that he makes about
skin care products:
Dr. Perricone is an Adjunct Professor of Medicine at the Michigan State University’s College
of Human Medicine. He is certiﬁed by the American Board of Dermatology, is a Fellow of
the New York Academy of Sciences, and a Fellow of the American College of Nutrition. He
is also a Fellow of the American Academy of Dermatology and the Society of Investigative
Dermatology. Dr. Perricone has served as Assistant Clinical Professor of Dermatology at
Yale School of Medicine and as Chief of Dermatology at the state of Connecticut’s Veterans
Hospital.
Dr. Perricone is the recipient of the Eli Whitney Award, presented by The Connecticut
Intellectual Property Law Association to an outstanding individual who has made signiﬁcant
contributions to science, invention, and technology. Prior recipients include National Medal
of Science beneﬁciary, Igor Sikorsky, (founder of Sikorsky aircraft) inventor of the ﬁrst
practical helicopter, which established the bedrock upon which today’s helicopter industry
rests, and Buckminster Fuller, inventor of the geodesic dome–the lightest, strongest, and
most cost-eﬀective structure ever devised. Dr. Perricone is also the recipient of the American
College for Advancement in Medicine (ACAM) 2000 Norman E Clark, Sr. Lecture Award
for his, “dedication and contributions towards advancing Complementary and Alternative
Medicine.”
43See Liang, supra note 8.
11It was during this time of receiving medical training that he developed his theory that “chronic inﬂammation
underlays symptoms of aging.” Dr. Perricone’s theory, despite medical skepticism, infra next paragraph, now
stands as heart of his success because it is the driving force of his cosmeceuticals skin care line and books.
According to the doctor, inﬂammation is caused by stress, dehydration, sun, sugar, and high-glycaemic
carbohydrates.
But it would take a bit more research for his trusting clientele to learn about the various criticisms that
have been lodged against the celebrity dermatologist by his professional peers. Because he has not published
studies in peer-reviewed journals proving that the main ingredients in his products indeed erase wrinkles,
it is doubtful that “he has been able to convincingly prove eﬃcacy of his products.”44 Instead, his peers
charge that his claims are contrary to scientiﬁc research in the area and that the claims are only based on
his own anecdotes.45 Moreover, although he touts his aﬃliation with Yale Medical School, his website does
not disclose that in 2002 Yale allowed Dr. Perricone’s appointment to expire because of the aforementioned
criticism in regards to his anti-inﬂammatory theories.46
B. Dr. Perricone – The Empire
Dr. Perricone’s theories are founded on shaky science. Yet and still Dr. Perricone has managed to amass a
large industry and consumer following.47 His name is ubiquitous as his products are retailed through national
chains such as Nordstrom and Sephora. Moreover, the “Perricone” name reaches worldwide purchasers
44Beatty, supra note 23 (quoting Dr. Leslie Baumann, director of cosmetic dermatology at the University of Miami, who
conducts clinical trials for the cosmetics and pharmaceutical industry).
45Krum, supra NOTE x. But see George W. Evans and Arnold I. Friede, The Food and Drug Administration’s Regulation
of Prescription Drug Manufacturer Speech: A First Amendment Analysis, 58 Food & Drug L.J. 365, 383 - 86 (arguing that
courts do not necessarily regard claims made in light of competing scientiﬁc claims to be “inherently misleading”).
46Beatty, supra note 8.
47Id.
12through his online website.48 He even has connections with big pharmaceutical companies. Though it seems
as if he meant to keep his link to pharmaceutical giant Johnson & Johnson a secret,49 the celebrity physician
is paid millions by the company to license his products.
C. Dr. Perricone - The Products
The fact that Perricone products are intentionally encased in the medicinal-looking brown jars and bottles
with scientiﬁc naming, and fact that they are priced at pharmaceutical like prices contribute to a sense that
these products are more than beauty products. And yet the FDA regulates these products in the same
manner that they would regulate a tube of lipstick.
C.
The Perricone Skin Care Line
Make no mistake; consumers’ economic interests are a stake when they purchase Perricone products. A
2-ounce vial of Alpha Lipoic Acid Face Firming Activator with NTP Complex and DMAE costs consumers
$95;50 $120 is the price tag on the Perricone Face Lipid Replenishment;51 and for his Neuropeptide Facial
Conformer, consumers are charged a whooping $570 for 2 ounces. But even his lower priced products are
48http://www.nvperriconemd.com/ (hereinafter referred to as “Perricone Online”).
49See Liang, supra note 8 (stating that “a conﬁdentiality agreement prevented [Dr. Perricone] from naming [the large company
paying him $150 million per year to license= his DMAE formulations”).
50Available at Perricone Online, supra note 42 (last visited May 6, 2005).
51Id.
13exorbitant: Moist Lips and Lip Plumper – products akin to Chapstick-run between $18 and $33.52
D. The Nutritional Supplements
In addition to the topical products, the Perricone arsenal also includes nutritional supplements. According
to his website “N.V. Perricone Nutriceuticalsr  [are] Nutritional supplements that work on the cellular
level, from the inside out, to help you achieve and maintain a more youthful, healthy look.” For instance,
Polysaccharide Peptide Blend” described as “a daily part of the Perricone Program [that provides the body
with] alpha-glucans, which help increase the energy in our cells and help the skin repair, renew, and revitalize
itself” are set at $60 per month. His Benfotiamine Capsules will cost a consumer $40 per month. And the
month long “Weight Management Program” – a cornucopia of nutritional supplements – is sold for $195.53
There is no denying Dr. Perricone’s connection to his product line. He “personally formulates every product”
that he promotes.54 This artiﬁcially exaggerates the drug-like mystique of his skin care line. Moreover, he also
carries a higher potency professional line only distributed to “qualiﬁed, licensed physicians, and to medical
spas with a qualiﬁed physician on staﬀ.”55 Since they are only distributed to these qualiﬁed professionals,
then much like ﬁlters on prescription drugs, they are presumably only available to the general public through
the same professionals. Based on all of this it is almost certain that the “ignorant, the unthinking, and the
52For a jocular insight on Perricone product pricing see Jeannie Kever, Paying a price by the Gallon, The Houston Chronicle
(April 29, 2004) (stating “the next time you’re ﬁlling up your SUV, be glad it doesn’t run on Dr. Perricone’s Neuropeptide
Facial Conformer. Twenty gallons of his wrinkle-ﬁghting cream would set you back $729,600”).
53Available at Perricone Online, supra note 42.
54Id.
55See http://www.drperricone.com/professional.htm (last visited April 30, 2005).
14credulous”56 consumers would be confused as to the nature of the Perricone products.
Dr. Perricone – The Books
E. The Labeling
Although the claims on the products’ packaging are relatively “mild,”57 the Wall Street Journal noted that in
contrast, Perricone’s books make claims that seem quite “fantastic.”58 Indeed, in one of his book Perricone
himself admits that his claims may seem “pretty lofty” he assures skeptical consumers that his claims “will
make perfect sense” once they understand how his program works.59 One can reasonably assume that the
manufacturers diﬀerentiated the product claims and the book claims so that they and the M.D. could avoid
the FDA’s drug regulations. Eﬀectively, Dr. Perricone, much like many other cosmeceutical entrepreneurs
is having is cake and eating it too – (or in this case having his cosmetics and selling it too): The claims on
the labels that are directly aﬃxed to his products are diluted.60 All of the real drug claims are made in his
books (and television promotionals) – a strategy which diverts FDA attention but still entices consumers to
purchase his products which they likely think have drug like eﬀects. But Perricone’s bifurcated marketing
strategy seems to overlook that the FDA might very well consider the books themselves product “labeling”
whose “fantastic” claims might in fact elevate the skin care line from mere “cosmetics” to more heavily
regulated drugs.
56See Liang, supra note 8, at 252 – 253 (citing Sudden Change).
57For instance his Eye Area Therapy System only states, in relevant part: “This unique eye care combination provides you
with the patented, powerful beneﬁts of Vitamin C Ester, Alpha Lipoic Acid, and DMAE.
Vitamin C Ester Eye Area Therapy cares for the delicate eye area, minimizing the appearance of ﬁne lines and revitalizing
stressed skin.
Alpha Lipoic Acid Eye Area Therapy provides energy to the skin, relieving the appearance of puﬃness and dark circles.”
58Beatty, supra note 23.
59The Perricone Prescription: A Physician’s 28-Day Program for Total Body and Rejuvenation, HarperResource
at xi (2002) (hereinafter referred to as “Perricone Prescription”).
60Of course, as argued in this paper, packaging, the pricing, the term “cosmeceutical,” and the doctor himself, should be
enough to mislead consumers. But FDA, however, has not ruled as such.
15As stated in the beginning of the paper, a product’s status as a drug or a cosmetic is determined by its
“intended use,” which can be assessed through its labeling.61 Under the law of the Food, Drug, and Cosmetics
Act, labeling includes, inter alia, “all labels and other written, printed, or graphic matter ...accompanying
[an] article.”62 Furthermore, the Supreme Court ruled that labeling is broader than the labels that are
on or in the article or package that is transported 63 – labeling includes freestanding books.64 Rather
than a physical connectedness, the textual relationship between the product and the literature seems most
important in determining whether a book is labeling a product.
There are several cases that provide guidance about what constitutes product labeling. U.S. v. 250 Jars
““Cal’s Tupelo Blossom U.S. Fancy Pure Honey””65 involved allegations of misbranded honey. A retail store
owner placed for sale on a shelf, jars of honey and copies of an independently authored literature about
honey.66 The court found that despite being sold separately, the literature and honey were interdependent
and part of an integrated distribution program.67 Then, invoking the imagery of the “unwary customer”
the court rejected the notion that the literature was not labeling simply because it referred to honey in
the generic sense, rather than to the speciﬁc honey that was being sold.68 From this case one can infer
that literature sold by the author that speciﬁcally refers to products sold by the author will be particularly
suspicious as product labeling.
61In general, however, “intended use” can be apprised from statements made by the company in any form or forum, see Hutt
and Merrile, supra note 19, at 386 (noting that the agency has relied on statements that a company has made in submissions
to the SEC).
6221 U.S.C. § 321.
63See Kordel v. United States, 335 U.S. 345, 350 (1948).
64See e.g. see U.S. Undetermined Quantities of Articles of Drug, 145 F.Supp2d 692 (D.Md.S.Div. 2001) (holding that “any
printed material, including books and pamphlets, which refers to or explains the usefulness of a drug product and which is
used, in any way, in its sale, accompanies the article in the statutory sense and constitutes “labeling,” for the purposes of
determining whether drug is misbranded...”).
65344 F.2d 288 (C.A.Mich. 1965).
66U.S. v. 250 Jars Cal’s Tupelo Blossom U.S. Fancy Pure Honey, 344 F.2d 288, 289 (6th Cir. 1965).
67U.S. v. 250 Jars, etc, 218 F.Supp. 208, 211-212 (D.C.Mich. 1963)
68U.S. v. 250 Jars, etc. of U.S. Fancy Pure Honey, 218 F.Supp. 208 at 212. (the appeals court integrated, by reference,
this lower court opinion into its ﬁnal opinion).
16Of course there are limits. The court in U.S. v. 24 Bottles ““Sterling Vinegar and Honey Aged in Wood
Cider Blended With Finest Honey Contents 1 Pint Product of Sterling Cider Co., Inc., Sterling, Mass””69
was faced with the question of whether books displayed in the same shop as an article “accompanied” the
article. The court made clear that “labeling does not include every writing which bears some relation to
the product;”70 but rather “[t]he distinguishing characteristic of a label is that, in some manner or another,
it is presented to the customer in immediate connection with his view and his purchase of the product.”71
The court did, however, intimate that books promoted in an “integrated transaction” with products may
constitute labeling for the products.72 In eﬀect, it is the “textual relationship” between product and book
is a signiﬁcant consideration.73
Based on these cases, and even though his books are not necessarily in “immediate connection” with a
purchasers view and purchase of his products,74 Dr. Perricone’s products and books should still be of
particular concern to the FDA based on these earlier cases. Indeed there is a textual relationship between the
product and books that make them seem as if they are part of an integrated transaction. Moreover, because
Dr. Perricone is both the author of his books and the creator of his products there is a stronger relationship
between these items than there were in the other cases where the books were created independent of the
products. And even more incriminatingly, the Perricone books actually direct consumers to his products.75
The points argued above couple with the courts’ inclination to protect unsuspecting consumers against sellers’
exploitation of loopholes,76 strongly suggests that the doctor’s bestselling series are part of the labeling for
69338 F.2d 157 (C.A.N.Y. 1964).
70Id. at 158.
71Id. at 159.
72U.S. v. 24 Bottles Sterling Vinegar and Honey Aged in Wood Cider Blended With Finest Honey Contents 1 Pint Product
of Sterling Cider Co., Inc., Sterling, Mass. 338 F.2d 157, 159 (C.A.N.Y. 1964).
73U.S. v. Diapulse Mfg. Corp. of America 389 F.2d 612, *616 (C.A.Conn. 1968).
74Though it might be argued that the online products which are sold on the same site as his books are indeed sold in the
“immediate connection” of one another.
75PAGES in PRESCRIPTION.
76See e.g. U.S. v. 250 Jars Cal’s Tupelo Blossom U.S. Fancy Pure Honey 344 F.2d 288, *289 (C.A.Mich. 1965)
17his skin care line.
F. The Drug Claims
Based on the legal deﬁnition of “drugs claims” there is almost no question that Dr. Perricone’s books assert
very strong drug claims. Generally claims that a product has physiological eﬀects will be suspect as drug
claims.77 Among the claims that have rendered products drugs are that use “scientiﬁc buzzwords” [such
as] ‘biologically aseptic’ while being made in a ‘pharmaceutical laboratory”’ and claims that the product
provides a “face lift without surgery.”78 Even claims that would seem to most as obvious exaggerations,
for instance that a commonplace household cooking sweetener honey is a “panacea for various diseases and
ailments” have been held by the courts to be problematic.79 “Less exaggerated” claims, however, will not
promote a product from a cosmetic to a drug.80
The genealogy of the title of Perricone’s ﬁrst book reveals that despite his cosmetics claims, the Perricone
philosophy and product line are truly intended to ﬁt into the medical realm. Dr. Perricone intended his
ﬁrst book for other medical professionals and accordingly, he originally entitled his ﬁrst book “Antioxidants
as Natural Anti-Inﬂammatories for Improvement of Cellular Function.” Though the substance of the book
remained untouched, his publishers later renamed it to its current more pop-friendly, consumer-enticing
title, The Wrinkle Cure.81 In The Wrinkle Cure Dr. Perricone enlightens readers as the causes of certain
dermatological problems, and then recommends a program of topical solutions and foods that can help
77Liang, supra note 8, at 253.
78Id. (quoting United States. V. An Article...Consisting of 216 Individually Cartoned Bottles, More or Less, of an Article
Labeled in Part:: Sudden Change, 288 F.Supp. 29 (E.D.N.Y. 1968).
79U.S. v. 250 Jars Cal’s Tupelo Blossom U.S. Fancy Pure Honey, 344 F.2d 288, 289 (6th Cir. 1965).
80United States v. An Article of Drug...47 Shipping Cartons, More or Less, ...“Helen Curtis Magic Secret,” 331 F.Supp.
912 (D.Md. 1971).
81See Liang, supra note 8.
18alleviate those problems.82
Beyond the “Cure” promised in the title of his ﬁrst book, the title of his next Bestseller, The Perricone Perscription,83
further establishes the pharmaceutical nature of his empire. In this bestseller, Dr. Perricone emphasized how
changes in eating habits can eﬀect dramatic changes in physical appearance and well-being. Accordingly, he
prescribes a speciﬁc program to reduce the cellular inﬂammation that he claims is related to skin aging and
other degenerative diseases.84 From these two books alone, it is clear that Dr. Perricone intends his products
as “prescriptions” to “cure” what his theory describes as the “degenerative disease” of inﬂammation and
aging.
In his most recent bestselling book, The Perricone Promise,85 Dr. Perricone continues breaking down his
theory to his audience of beauty-hungry consumers.86 In this book, the doctor reveals a “groundbreaking
program that helps reverse the aging process – inside and out.... Dr. Perricone’s revolutionary program
utilizes the biggest breakthrough in anti-aging medicine in years, protein-like substances called peptides and
neuropeptides. These powerful compounds revitalize skin and hair, promote heart health, help decrease the
risk of certain forms of cancer, strengthen the immune system...”87 Thusly, even though the claims on the
labels physically aﬃxed to the skin care products are mild, the claims on made in the Perricone books –
books that consumers are likely to readily associate with his skin care product line, should concern the FDA.
The Perricone website provides even more fuel for the argument that Perricone products are intended as
82See generally Nicholas Perricone, M.D., The Wrinkle Cure, Warner Books (2000).
83The Perricone Prescription, supra note 58.
84Id.
85Nicholas Perricone, M.D., The Perricone Promise : Look Younger, Live Longer in Three Easy Steps, Warner Books
(2004) (hereinafter referred to as “Perricone Promise”)
86Consumers such as myself.
87Perricone Promise, supra note 84, at front cover ﬂap.
19drugs.88 On one page consumers can “Consult [the] Doctor” through a chart that prescribes various items
in his skin care line to remedy various ailments (such as “dry, dehydrate” skin and “loss of tone, sagging”).89
In contrast to the “less exaggerated” claims that past muster in the courts, Dr. Perricone’s assertions have
been described by him and others as “fantastic” and “lofty.” Moreover, if the court were concerned that
claims that a well-known, household grocery item would confuse consumers to actually believing that it
could cure various diseases and ailments then they would be even more concerned about the less-familiar
Perricone cosmeceuticals promoted in literature by a famous, well established physician who indeed oﬀers
his products as an alternative to surgery that will cure degenerative diseases. Perricone cosmeceuticals are
drugs and should be regulated as such.
G. A Drug in Cosmetic’s Clothing
In light of the totality of circumstances – the clinical packaging, the clinical monikers, the appendage “ceu-
tical,” the “Cure,” the “Prescription,” the drug-like pricing, the association with and endorsement by a
renowned Yale Medical School dermatologist, – it would be a wonder if consumers realized that they were
purchasing products that have in actuality been regarded by the FDA as nothing more than cosmetics –
akin to a tube of lipstick or a bottle of nail polish.
Moreover, if his products are indeed drugs, Dr. Perricone might be forced to prove the eﬃcacy of his claims
under the FDA’s new drug approval process.90 Seeing as he has not published in any peer-reviewed journals
88Please note that the status of websites as labeling or advertising is unresolved. See Evans and Friede, supra note 45 at 373.
See id. at 378 -80, for an argument that websites are akin to labeling and therefore should be regulated by the FDA.
89See http://www.drperricone.com/consultthedoctor.htm (last visited April 30, 2005).
90Evans and Friede, supra note 45, at 375.
20and the veracity of his claims as been strongly questioned within the medical ﬁeld a drug designation might
shatter his empire.
H. Dr. Perricone – The Defenses
Admittedly, the case that Perricone products are drugs might not be as clear-cut as implied in the sections
above. First, the disclaimers in his books and online might negate the drug-like nature of the claims in these
publications. Second, the First Amendment might protect his books and claims from regulatory scrutiny.
Finally, the public may actually beneﬁt from the information that he disseminates in his books and online
publications.
I. Disclaimers
The point may seem obvious, but the presence of a disclaimer, might make it more diﬃcult to place these
Perricone products in the “drug” box. One such disclaimer reads: “This book is written as a source of
information only. The information contained in this book should by no means be considered a substitute
for the advice of a qualiﬁed medical professional, who should always be consulted before beginning any new
diet, exercise or other health program...The author and the publisher expressly disclaim responsibility for
any adverse eﬀects arising from the use or application of the information contained herein...” Online, his
disclaimer states that “[t]hese statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.”91 However, this defense
might prove weak under the shadow of Pasadena Research Laboratories v. U.S., where the court condemned
91Perricone Online, supra note 42.
21disclaimers as “scientiﬁc double-talk.” 92
J. First Amendment Rights
Though for the sake of regulation and consumer protection the books should be considered labeling as
argued above, Dr. Perricone and his books might still arguably be protected by the First Amendment right
to freedom of speech. The world of ﬁrst amendment protected speech can be divided into three general
categories: 1) low level protection of commercial speech;93 2) high level protection of non-commercial speech
and 3) non-protection of ﬁghting words, obscenity, threats, etc. Perricone’s books are clearly not “ﬁghting
words;” therefore they will likely be subject to some sort of protection. The question is how much?
In assessing commerciality, courts will determine whether “1) the speech at issue is conceded to be an
advertisement; 2) the speech refers to a particular product; and 3) the speaker has an economic motive.”94
If Perricone’s books were actually labels that were physically aﬃxed to the products in his skin care line,
one could be comfortable arguing that they were commercial speech as they were attached to products that
were being sold commercially. But the idea that these books are “labeling” as we commonly understand
the term is merely the magic of the FDA’s broad regulatory deﬁnitions. Perricone’s books are, in actuality,
freestanding publications; and it is a longstanding practice that the First Amendment protects published
materials.95 In that sense, it might seem obvious that the bestsellers are protected speech that should be
exempt from regulatory oversight.
92169 F.2d. 375, 383 (9th Cir. 1948).
93See Commercial Advertising and Virginia State Bd. of Pharm. v. Virginia Citizens Consumer Council, 425 U.S. 748
(1976) (overruling an earlier decision that exempted commercial speech from the protection of the First Amendment, the
Supreme Court here held that commercial speech is low value speech that receives First Amendment protection).
94Evans and Friede, supra note 5, at 383.
95See Chneck v. U.S., 249 U.S. 47 (1919) (holding that published materials are protected under the First Amendment as
long as they present no clear and present danger to the public).
22The status of the books, however, seems more unclear than not, especially in light of recent Supreme Court
cases grappling with the diﬃcult question of the intersection between commercial speech, non-commercial
speech, and issues of public importance.96 Similarly here there are two strong competing interests: First the
FDA broad mandate to protect consumers against rogue cosmetics (and their inﬁrmed labels) and second,
the constitutional guarantee of the right to free speech. Ultimately, Dr. Perricone’s best line of defense
against the FDA’s duty to protect consumers might be to argue that his books are protected speech because
they are traditional publications rather than mere commercial speech since he does not refer to them as
advertisements and makes no reference to any particular products in his product line.97
K.
Public Good
One ﬁnal policy argument aid Dr. Perricone’s defense. Even if his products are in fact drugs, they should
not receive the burdensome drug regulation because there are arguable beneﬁts to his “direct to consumer”
96See Nike v. Kasky, 539 U.S. 654 (2003) (presents what was at the time a novel First Amendment questions because
the speech at issue represented a blending of commercial speech, noncommercial speech, and debate on an issue of public
importance. Commercial enterprise Nike was accused of abusive labor practices which it responded to in various newspapers
and publications.).
97Although Perricone does make passing reference to his own products, his books do not speciﬁcally relate to his products.
Instead the books detail a holistic nutrition and cosmetic regime that works “synergistically” with his products. In the text
of the books there are no direct mentions of speciﬁc products of in his product line. He does however provide the addresses
of online websites where consumers can purchase cosmeceuticals that would generally ﬁt into the regimen that he advocates.
The sticky issue is that even though he seems to be directing readers to an array of other online cosmeceutical products, in fact
for all of the sites that consumers are directed to only sell his line of products. So, de facto, his books refer to his particular
products.
In another twist, at the back of the Perricone Promise is a special promotional where the doctor directs consumers to his
website to purchase a certain amount of his products in order to receive two of his eye therapy products for free. It is not clear
where this type of product placement would fall in the realm of commercial speech jurisprudence.
23advertising approach. It is an argument that is broadly applicable to more than just Dr. Perricone’s
products. As the argument goes, disseminating information empowers consumers to make decisions about
their healthcare and their health care regimes, especially when they might have more information about
their conditions than do doctors. He could in fact argue that direct to consumer information is vital for the
vitality of our American consumership.98
Conclusion
As they have done with the pharmaceutical industry,99 the FDA may have to expand its jurisdiction to check
the practices of these physicians that consumers – the consumers that the FDA is charged with protecting
– are relying on to guide their cosmetic purchasing choices. Or perhaps it is just a matter of creating a new
regulatory category that would provide clear guidance to cosmeceuticals companies about exactly how to
and to cosmeceuticals purchasers about what they can expect from the products. No matter the strategy
that the FDA ultimately employs, it is clear that the cosmetics industry’s parading of dermatologists to sell
their products to credulous consumers should be a matter of concern for us all.
98For the counter to this argument see Jeﬀrey P. Kahn, Ph.D., M.P.H, The Double-Edged Sword of Drug Marketing, Ethics
Matters (August 9, 1999) available at http://www.cnn.com/HEALTH/bioethics/9908/drug.marketing/ (last visited May 8,
2005) (arguing that even though there is value in drug advertising the downsides include a proliferation of false or misleading
information, and an upheaval of the traditional doctor-patient relationship).
99See Chen, supra note 32, at 473 – 74.
24